Precancerous Conditions  >>  NOV-002  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NOV-002 / Cellectar
NCT00960726: NOV-002 in Myelodysplastic Syndrome (MDS)

Withdrawn
2
0
US
NOV-002
M.D. Anderson Cancer Center, Cellectar Biosciences, Inc.
Leukemia, Myelodysplastic Syndrome
 
 

Download Options